The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.
Hypoglycaemia in Type 2 diabetes
Open accessAbstract
The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in particular, those which raise insulin levels independently of blood glucose, such as sulphonylureas (SUs) and exogenous insulin. The risk of hypoglycaemia is increased in older patients, those with longer diabetes duration, lesser insulin reserve and perhaps in the drive for strict glycaemic control. Differing definitions, data collection methods, drug type/regimen and patient populations make comparing rates of hypoglycaemia difficult. It is clear that patients taking insulin have the highest rates of self‐reported severe hypoglycaemia (25% in patients who have been taking insulin for > 5 years). SUs are associated with significantly lower rates of severe hypoglycaemia. However, large numbers of patients take SUs in the UK, and it is estimated that each year > 5000 patients will experience a severe event caused by their SU therapy which will require emergency intervention. Hypoglycaemia has substantial clinical impact, in terms of mortality, morbidity and quality of life. The cost implications of severe episodes—both direct hospital costs and indirect costs—are considerable: it is estimated that each hospital admission for severe hypoglycaemia costs around £1000. Hypoglycaemia and fear of hypoglycaemia limit the ability of current diabetes medications to achieve and maintain optimal levels of glycaemic control. Newer therapies, which focus on the incretin axis, may carry a lower risk of hypoglycaemia. Their use, and more prudent use of older therapies with low risk of hypoglycaemia, may help patients achieve improved glucose control for longer, and reduce the risk of diabetic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 The effect of duration of diabetes on the proportion of patients experiencing severe hypoglycaemic episodes. The open circles represent patients in the intensive arm in the United Kingdom Prospective Diabetes Study (UKPDS) and show an increase in the proportion of patients experiencing a severe hypoglycaemic event over time. In contrast the closed circles represent patients in the diet-only arm of UKPDS and do not show an increase [21]. Reprinted from The Lancet, 352: UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, 837–853, Copyright 1998, with permission from Elsevier.](/paper-figures/5adfd753fd3c48a49c2f7cc1937c5bb1/hypoglycaemia-in-type-2-diabetes-figure-1.jpg)
![FIGURE 2 Proportion of patients with Type 2 and Type 1 diabetes of differing durations and receiving different regimens experiencing at least one severe hypoglycaemic attack during 9–12 months’ follow-up. All patients were receiving insulin except the group treated with sulphonylurea [35]. Reproduced from [35] with kind permission of Springer Science and Business Media.](/paper-figures/e7b9acd663cc4480b7a0ff16afdffc1f/hypoglycaemia-in-type-2-diabetes-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“plasma glucose concentrations ≤3.9 mmol/l (70 mg/dl) sometimes occur in non-diabetic individuals [1,3].This is true, particularly in women and children, albeit generally during prolonged fasting.”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [3]
In the citing paper
“they recommend a therapeutic plasma glucose concentration lower limit of 4.0-4.5 mmol/l (72-81 mg/dl).”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [3]
In the citing paper
“Amiel et al. [3] also suggest a value of 3.5 mmol/l (63 mg/dl).”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [3]
In the citing paper
“However, maintaining glycaemic control in patients is no easy task, as hypo- or hyperglycaemia can result from administration of the currently available treatments resulting in either too much or not enough, respectively, of an anti-hyperglycaemic effect.3,48”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Research works printed but not linked: 3
- Canadian Diabetes Association, 2003, Hypoglycemia, Can J Diabetes, 27, S43
- 10.1210/jc.82.5.1458 · DOI
- Curtis L, 2006, Unit Costs of Health and Social Care
Cited by
Sorted by citations
Items 201–300 of 472
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 22
Social vulnerability and hypoglycemia among patients with diabetes
Waitman, J. N., Caeiro, G., Gonzalez, S. A. R., Ré, D. P., DAGHERO, A. V., González, C. D., & Umpierrez, G. E. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.11.008 · Cited by 25
Economic burden of hypoglycemia for type II diabetes mellitus patients in Malaysia
Aljunid, S. M., Aung, Y. N., Ismail, A., Rashid, S. A. Z. A., Nur, A. M., Cheah, J., & Matzen, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211248 · Cited by 22
Yee, J., Heo, Y., Kim, H., Yoon, H. Y., Song, G., & Gwak, H. S. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.008 · Cited by 21
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Umetsu, R., Nishibata, Y., Abe, J., Suzuki, Y., Hara, H., Nagasawa, H., Kinosada, Y., & Nakamura, M. (2014) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.13-00225 · Cited by 20
Charbonnel, B. H., Schweizer, A., & Dejager, S. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1059 · Cited by 20
Simeone, J. C., & Quilliam, B. J. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q352 · Cited by 20
Newswanger, B., Prestrelski, S. J., & Andre, A. D. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1653278 · Cited by 20
Dejager, S., Detournay, B., Halimi, S., Robert, J., & Deschaseaux, C. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s84507 · Cited by 20
Schweizer, A., Halimi, S., & Dejager, S. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54585 · Cited by 20
In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus
Kim, S. R., Kim, D., Park, S. H., Kim, Y. S., Kim, C. H., Ha, T.-Y., Yang, J. W., & Rhee, J.-K. (2013) · Journal of Diabetes Research · doi:10.1155/2013/269569 · Cited by 20
Hypoglycemia and diabetes: increased need for awareness
Shaefer, C. F., Hinnen, D., & Sadler, C. E. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1163255 · Cited by 21
Penfornis, A., Bourdel‐Marchasson, I., Quéré, S., & Dejager, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.003 · Cited by 19
Quality of life and fear for hypoglycemia in patients with type 2 diabetes mellitus
Jódar-Gimeno, E., Guisasola, F. Á., Lachica, L. Á., Palomares-Ortega, R., Roldán-Suárez, C., & Lizán-Tudela, L. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.07.003 · Cited by 19
Bader, G., Geransar, P., & Schweizer, A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.011 · Cited by 19
Amate, J., López-Cuadrado, T., Almendro, N., Bouza, C., Saz-Parkinson, Z., Rivas-Ruíz, R., & González-Canudas, J. (2015) · International journal of clinical practice · doi:10.1111/ijcp.12605 · Cited by 17
Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus
Brunton, S. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2570 · Cited by 19
Raju, A., Shetty, S. S., Cai, B., & D’Souza, A. O. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.5.483 · Cited by 19
Ma, S., Schreiner, P. J., Seaquist, E. R., Ugurbil, M., Zmora, R., & Chow, L. S. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2020.103379 · Cited by 20
Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
Oyagüez, I., Peralta, F. G., Artola, S., Carrasco-Sánchez, F. J., Carretero‐Gómez, J., Soidán, F. J. G., Gómez‐Huelgas, R., Merino-Torres, J. F., & Pérez, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01064-4 · Cited by 24
Jódar-Gimeno, E., Guisasola, F. Á., Lachica, L. Á., Palomares-Ortega, R., Roldán-Suárez, C., & Lizán-Tudela, L. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.07.009 · Cited by 18
McGill, J. B., Barnett, A. H., Lewin, A. J., Patel, S. D., Neubacher, D., von Eynatten, M., & Woerle, H. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113507068 · Cited by 18
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 18
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17
Quilliam, B. J., Ozbay, A. B., Sill, B. E., & Kogut, S. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12217 · Cited by 17
Increasing awareness of hypoglycaemia in patients with Type 2 diabetes treated with oral agents
Barnett, A. H., Brice, R., Hanif, W., James, J., & Langerman, H. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.834250 · Cited by 20
Goh, S., Hussein, Z. B., & Rudijanto, A. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12647 · Cited by 16
Managing diabetes in people with dementia: a realist review
Bunn, F., Goodman, C. M., Jones, P. R., Russell, B., Trivedi, D. P., Sinclair, A. J., Bayer, A. J., Rait, G., Rycroft‐Malone, J., & Burton, C. R. (2017) · Health Technology Assessment · doi:10.3310/hta21750 · Cited by 20
Crim, W. S., Wu, R., Carter, J. D., Cole, B. K., Trace, A. P., Mirmira, R. G., KUNSCH, C. A., Nadler, J. L., & Nunemaker, C. S. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.02.041 · Cited by 17
Boglou, P., Steiropoulos, P., Παπάνας, Ν., & Bouros, D. E. (2013) · BMJ Case Reports · doi:10.1136/bcr-2012-008528 · Cited by 17
Illness integration, self-management and patient-centred support in type 2 diabetes
Jutterström, L. (2013) · DiVA at Umeå University (Umeå University) · Cited by 16
HIGHTON, P. J., Funnell, M. P., Gupta, P., Zaccardi, F., Lim, L., Seidu, S., & Khunti, K. (2025) · Diabetologia · doi:10.1007/s00125-025-06617-x · Cited by 26
Nanjala, C., Ren, J., Mutie, F. M., Waswa, E. N., Mutinda, E. S., Odago, W. O., Mutungi, M. M., & Hu, G. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114822 · Cited by 18
Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2
Hanefeld, M., Ganz, X., & Nolte, C. (2014) · Herz · doi:10.1007/s00059-014-4086-1 · Cited by 17
DAILEY, G. E., Gao, L., Aurand, L. A., & Garg, S. K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12131 · Cited by 16
Oshima, H., Yoshida, S., Ohishi, T., Matsui, T., Tanaka, H., Yonetoku, Y., Shibasaki, M., & Uchiyama, Y. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.11.015 · Cited by 16
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 17
Meneghini, L., Lee, L. K., Gupta, S., & Preblick, R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13208 · Cited by 16
Peralta, F. G., Pérez, J. A. F., Molinero, A., Barrancos, I. M. S., Martínez, E. A., Martínez-Pérez, P., Mera-Gallego, I., & Rodríguez, N. F. A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002148 · Cited by 17
Prevention and management of transplant-associated diabetes
Jenssen, T. G., & Hartmann, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.628936 · Cited by 16
Viriato, D., Calado, F., Gruenberger, J.-B., Ong, S. H., Carvalho, D. M., Silva‐Nunes, J., Johal, S., & Viana, R. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.912986 · Cited by 16
Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Bonadonna, R. C., Renard, É., CHENG, A. Y. Y., Fritsche, A., Cali, A. M. G., Melas‐Melt, L., & Umpierrez, G. E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.041 · Cited by 16
for the PROFAST Study Group, Elhadd, T. A., Dabbous, Z., Bashir, M., Elzouki, A.-N. Y., Ghadban, W., Baagar, K. A. M., Benjamin, S., Hassanien, M. A., Saeed, A., et al. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0374-2 · Cited by 16
Odawara, M., Kadowaki, T., & Naito, Y. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-20 · Cited by 15
Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting
Palmer, J. L., Knudsen, M. S., Aagren, M., & Thomsen, T. L. (2010) · Journal of Medical Economics · doi:10.3111/13696991003723999 · Cited by 15
Gu, S., Deng, J., Shi, L., Mu, Y., & Dong, H. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1049542 · Cited by 15
Gu, W., Ren, Y., Ji, L., Hong, T., Mu, Y., Guo, L., Li, Q., Tian, Q., & Yang, X. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.024 · Cited by 16
Dalal, M. R., Kazemi, M. R., & Ye, F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1248911 · Cited by 14
Olsen, M. T., Klarskov, C. K., Hansen, K. B., Pedersen‐Bjergaard, U., & Kristensen, P. L. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108803 · Cited by 14
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.767892 · Cited by 14
Cheng, P. C., Hsu, S. R., Tu, S., Cheng, Y. C., & Liu, Y. H. (2018) · PeerJ · doi:10.7717/peerj.4348 · Cited by 16
Chantzaras, A. E., & Yfantopoulos, J. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.10.005 · Cited by 14
Songtrai, S., Pratchayasakul, W., Arunsak, B., Chunchai, T., Kongkaew, A., Chattipakorn, N., Chattipakorn, S. C., & Kaewsuwan, S. (2022) · Nutrients · doi:10.3390/nu14224895 · Cited by 14
Potential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Villani, M., Earnest, A., Smith, K. L., Giannopoulos, D., Soldatos, G., de Courten, B. V., & Zoungas, S. (2019) · Diabetologia · doi:10.1007/s00125-019-4933-y · Cited by 14
Kaewput, W., Thongprayoon, C., Rangsin, R., Bathini, T. J., Torres‐Ortiz, A., Mao, M. A., & Cheungpasitporn, W. (2020) · Endocrine Research · doi:10.1080/07435800.2020.1792921 · Cited by 13
Moisan, J., Breton, M.-C., Villeneuve, J., & Grégoire, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.039 · Cited by 13
Sanad, F. A.-A., Ahmed, S. F., & El-Tantawy, W. H. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1722705 · Cited by 13
Hypoglycaemia in type 2 diabetes
MacArthur, C. (2010) · Practice Nursing · doi:10.12968/pnur.2010.21.4.47394 · Cited by 13
Gilet, H., Gruenberger, J.-B., Bader, G., & Viala-Danten, M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.002 · Cited by 13
Kalra, S., Deepak, M., Narang, P., Singh, V., Uvaraj, M. G., & Agrawal, N. K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0237 · Cited by 13
Jadhav, S., Mane, R. M., Narayanan, K. L., & Bhosale, P. N. (2016) · Scientia Pharmaceutica · doi:10.3390/scipharm84040671 · Cited by 13
Dietary treatment of hypoglycaemia: should the Australian recommendation be increased?
Vindedzis, S., Marsh, B., Sherriff, J., Dhaliwal, S., & Stanton, K. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02831.x · Cited by 12
Chen, M., Liu, Y., Jin, J., & He, Q. (2016) · Renal Failure · doi:10.3109/0886022x.2016.1149682 · Cited by 12
Hypoglycemia in type 2 diabetes
LeBras, M. H., & Laubscher, T. A. (2021) · Canadian Family Physician · doi:10.46747/cfp.670135 · Cited by 12
Survival in people with type 2 diabetes as a function of HbA1c
Balkau, B., & Simon, D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62192-9 · Cited by 12
Linagliptin safety profile: A systematic review
Gomes, G. K. A., Ramos, A. I. D. C., Sousa, C. T., Sanches, C., Pereira, M. L., & Baldoni, A. O. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.04.006 · Cited by 12
Shafie, A. A., Ng, C. H., Thanimalai, S., Haron, N., & Manocha, A. B. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0369-z · Cited by 12
Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes
Schwartz, S. J. (2013) · Drugs in Context · doi:10.7573/dic.212255 · Cited by 12
Hassoun, A. A. K., Alarouj, M., & Ibrahim, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1243093 · Cited by 12
Saulnier, P., Briet, C., Gand, E., Chaillous, L., Dubois, S. G., Bonnet, F., Leguerrier, A.-M., Fradet, G., Crespin, I. D., Kerlan, V., et al. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.003 · Cited by 13
Revisiting hypoglycemia in diabetes
Gehlaut, R. R., & Shubrook, J. H. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2013.08.002 · Cited by 11
The older patient with diabetes: a practical approach
Ben‐Yehuda, A., Zinger, A., & Durso, S. C. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2485 · Cited by 11
Kattan, W., & Abduljawad, A. A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.031 · Cited by 11
Pilemann-Lyberg, S., Thorsteinsson, B., Nørgaard, K., Zander, M., Vestergaard, H., & Røder, M. E. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.09.006 · Cited by 11
Rauh, S. P., Rutters, F., Thorsted, B. L., Wolden, M. L., Nijpels, G., van der Heijden, A. A. W. A., Walraven, I., Elders, P. J. M., Heymans, M. W., & Dekker, J. M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012793 · Cited by 12
Martín-Vaquero, P., Martínez‐Brocca, M. A., & López, J. M. G. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.08.003 · Cited by 11
Ikeda, Y., Kubo, T., Oda, E., Abe, M., & Tokita, S. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12959 · Cited by 11
Management of Diabetic Nephropathy in the Elderly: Special Considerations
Rahman, E. M. A. (2012) · Journal of Nephrology & Therapeutics · doi:10.4172/2161-0959.1000124 · Cited by 11
Tripp, M. L., Darland, G. K., Konda, V. R., Pacioretty, L. M., Chang, J., Bland, J. S., & Babish, J. G. (2012) · Nutrition Research and Practice · doi:10.4162/nrp.2012.6.5.405 · Cited by 11
Woo, V. C., Bell, A., CLEMENT, M. A., Noronha, L., Tsoukas, M. A., Camacho, F., Traina, S., Georgijev, N., Culham, M. D., Rose, J. B., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13573 · Cited by 11
Yunir, E., Nugraha, A. R. A., Rosana, M., Kurniawan, J., Iswati, E., Sarumpaet, A., Tarigan, T. J. E., & Tahapary, D. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-43459-2 · Cited by 13
Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care
Kostev, K., Dippel, F. W., & Rathmann, W. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.08.001 · Cited by 10
Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
SENNIK, D. K., Ahmed, F. W., & Russell-Jones, D. L. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.79 · Cited by 10
Jafari, B., & Britton, M. E. (2015) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1163 · Cited by 11
Torre, C., Guerreiro, J., Romano, S., Miranda, A., Longo, P., Alão, S., Conceição, J., & Laires, P. A. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.06.001 · Cited by 10
Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon
D’hers, S., Vazquez, A. N. A., Gurman, P., & Elman, N. M. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00615-4 · Cited by 10
Cross-cultural variation in symptom perception of hypoglycemia
Kalra, S., Balhara, Y. P. S., & Mithal, A. (2013) · Journal of Mid-life Health · doi:10.4103/0976-7800.118998 · Cited by 10
Incidence and risk factors of hypoglycemia among Type 2 diabetic patients in a South Indian hospital
Vikas, P., Chandrakumar, A., Dilip, C., Suriyaprakash, T. N. K., Thomas, L., & Surendran, R. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.014 · Cited by 11
Ampudia‐Blasco, F. J., Galán, M., & Brod, M. I. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.03.008 · Cited by 10
Reid, L. A., Zheng, S., Mendoza, J. A., Reboussin, B. A., Roberts, A. J. C., Sauder, K. A., Lawrence, J. M., Jensen, E. T., Henkin, L. F., Flory, K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1807 · Cited by 9
Alonso-Morán, E., Orueta, J. F., & Nuño-Solínis, R. (2015) · BMC Health Services Research · doi:10.1186/s12913-015-0876-2 · Cited by 9
Recognizing and minimizing hypoglycemia: The need for individualized care
Lavernia, F., Kushner, P. R., Trence, D., Rice, D., DAILEY, G. E., & Kuritzky, L. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1086628 · Cited by 10
Fears and concerns of Iranian diabetic women: A phenomenological study
Aghamohammadi, M., & Valizadeh, S. (2014) · Journal of Health Psychology · doi:10.1177/1359105314552303 · Cited by 10
Hassoun, A. A. K., Pathan, M. F., Medlej, R., Alarouj, M., Shaltout, I., Chawla, M. S., Knap, D., & Vaz, J. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s103692 · Cited by 9
Leinwand, B., Johnsrud, M. T., Nguyen, A. P., Meyer, J. H., & Johnson, K. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1742131 · Cited by 9
Optimal utilisation of sulphonylureas in resource-constrained settings : review article
Naidoo, P., Rambiritch, V., Butkow, N., & Saman, S. (2014) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2014-007 · Cited by 9
Factors Influencing Variations in Hospitalization for Diabetes with Hypoglycemia
Kattan, W., & Wan, T. T. H. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100367 · Cited by 10
Hayek, A. A., Robert, A. A., & Dawish, M. A. A. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419834935 · Cited by 9
Metadata
- Authors
- Amiel, S. A., Dixon, T., Mann, R., & Jameson, K.
- Affiliations
- King's College London (GB)
- University of Sheffield (GB)
- MSD (UK) Limited (United Kingdom) (GB)
- Corresponding author
- Amiel, S. A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2008-02-27
- Volume
- 25
- Issue
- 3
- Pages
- 245-254
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- PMC
- PMC2327221
- OpenAlex
- W2156888511
- Cited by
- 472
- References
- 77
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 10 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 15 · 2019: 22 · 2018: 34 · 2017: 17 · 2016: 29 · 2015: 33 · 2014: 46 · 2013: 55 · 2012: 46
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetic Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, type 2 diabetes, sulfonylureas, insulin therapy, severe hypoglycemia, glycemic control, incretin-based therapy, hospital costs, diabetes complications
- MeSH terms
- Diabetes Mellitus, Type 2, Hospitalization, Humans, Hypoglycemia, Insulin, Risk Factors, Sulfonylurea Compounds, Antidiuretic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
